Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 16;11(3):e005301. doi: 10.1136/jitc-2022-005301

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Percentage change in sum of target lesion diameters from baseline in (A) Part 1 dose escalation (GSK3174998 alone), (B) Part 2 dose escalation (GSK3174998+pembrolizumab), and (C) Part 2 dose expansion (GSK3174998+pembrolizumab; one patient with soft tissue sarcoma was not evaluable) assessed using irRECIST. irRECIST, immune-related Response Evaluation Criteria in Solid Tumors; PD-1, programmed cell death 1 protein; PD-L1, programmed cell death 1 ligand.